LONDON, July 11, 2023 (GLOBE NEWSWIRE) — PMcardio, a leading force in AI-powered diagnostics for cardiovascular diseases, announces expansion into 15 additional European markets with the launch of its newest version. After a successful initial launch in the United Kingdom, with over 25 000 registered users, PMcardio is now making its […]
Coronary/Structural Heart
Renibus Therapeutics Announces Breakthrough Therapy Designation from US FDA for RBT-1 for the Reduction in Risk of Post-Operative Complications in Patients Undergoing Cardiothoracic Surgery
SOUTHLAKE, Texas, July 11, 2023 /PRNewswire/ — Renibus Therapeutics, Inc., (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to RBT-1 for the reduction in risk of post-operative complications in patients undergoing cardiothoracic […]
First U.S. Patients Implanted with Innovative FIRE1 Remote Heart Failure Monitoring System in Early Feasibility Study
DUBLIN–(BUSINESS WIRE)– FIRE1 today announced that the first U.S. patients have been successfully implanted with its FIRE1™ System for remote heart failure monitoring in an Early Feasibility Study. The study will assess FIRE1’s novel solution to improve outcomes for heart failure patients. The first patient was implanted at Austin Heart, Texas, where […]
US FDA approves expanded indication for Novartis Leqvio® (inclisiran)
EAST HANOVER, N.J., July 10, 2023 /PRNewswire/ — Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy1. […]
Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure
US study seeking to confirm strong efficacy data reported in RED DESERT and SAHARA Initial data expected in Q4 2023 Ghent, Belgium – 10 July 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the first patient has been enrolled […]
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
PRINCETON, N.J., July 07, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has completed enrollment of the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) randomized, controlled trial, evaluating the […]
1,000th alfapump® implant completed
Extensive real world alfapump experience derisks planned US & Canadian launch Strong clinical alfapump profile demonstrated in North American POSEIDON study All approvals received to commence US MOJAVE study of DSR 2.0 Ghent, Belgium – 06 July 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), […]
Cardio Diagnostics Holdings, Inc and RiverRock Medical Partner to Bring Epigenetic-Genetic Heart Disease Testing to Austin, Texas
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, announced a partnership with Austin, Texas-based concierge, and executive health practice, RiverRock Medical. This partnership establishes RiverRock Medical as the first service provider in Austin, Texas, to incorporate Epi+Gen CHD and PrecisionCHD, state-of-the-art epigenetic-genetic heart […]
Medtronic Statement on ESH Guidelines for Hypertension and Renal Denervation
DUBLIN–(BUSINESS WIRE)–Medtronic is excited by the updated European Hypertension Society (ESH) guidelines that highlight the role of renal denervation (RDN) as part of the hypertension care pathway. The guidelines were announced at the ESH 32nd Annual Meeting and simultaneously published in the Journal of Hypertension. This marks a turning point for RDN […]
BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency
SUNNYVALE, Calif. , July 05, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it completed its submission of the CardiAMP Cell Therapy System to Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards approval for the […]



